Abstract: A peelable coating composition capable of providing coating films with good peelability particularly after UV exposure and desirable mechanical properties.

Abstract: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: A low dropout linear regulator, a starting method, an electronic device, and a chip are provided. Wherein the low dropout linear regulator comprises an error amplifier circuit, an over current circuit and an over-current adjustor, the starting method includes: beginning a soft-starting process of the low dropout linear regulator and turning on a first transistor and a second transistor to provide a over current to raise an output voltage of the low dropout linear regulator; maintaining the ‘turn on’ state of the first transistor and the second transistor and decreasing the over current according to a signal obtained from the error amplifier circuit after the output voltage of the low dropout linear regulator reaches a starting voltage of the error amplifier circuit; wherein the error amplifier circuit begins to operate when the output voltage of the low dropout linear regulator reaches the starting voltage of the error amplifier circuit.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: A low dropout linear regulator, a starting method, an electronic device, and a chip are provided. Wherein the low dropout linear regulator comprises an error amplifier circuit, an over current circuit and an over-current adjustor, the starting method includes: beginning a soft-starting process of the low dropout linear regulator and turning on a first transistor and a second transistor to provide a over current to raise an output voltage of the low dropout linear regulator; maintaining the ‘turn on’ state of the first transistor and the second transistor and decreasing the over current according to a signal obtained from the error amplifier circuit after the output voltage of the low dropout linear regulator reaches a starting voltage of the error amplifier circuit; wherein the error amplifier circuit begins to operate when the output voltage of the low dropout linear regulator reaches the starting voltage of the error amplifier circuit.

Abstract: A clutch assembly for a lock includes a driver (1), having a driver shaft (9); a coupler (3); and a follower (2). The driver (1), the coupler (3) and the driver shaft (9) are configured to rotate concentrically together. The coupler (3) is configured to move along the central axis of the driver shaft (9) to couple to or decouple from the follower (2). The driver (1) and the follower (2) are configured to rotate concentrically together when the coupler (3) is engaged to the follower (2), and wherein the driver (1) and the follower (2) are configured to rotate independently when the coupler (3) is disengaged from the follower (2).

Abstract: A double clutch assembly includes a first clutch assembly and a second clutch assembly. The first clutch assembly includes a cylinder (21), a driver assembly, comprising a control member (11), a driver (1), and a driver shaft (9), wherein the control member (11), the driver (1), the driver shaft (9) and are configured to rotate concentrically together and a follower (2). The cylinder (21) is connected to the driver shaft (9). The rotation of the cylinder (21) causes the driver shaft (9) to engage with or disengage from the follower (2). The second clutch assembly includes an actuating assembly and a coupler (3). The coupler (3) relates to and is configured to rotate concentrically with the driver assembly. The actuating assembly is operably connected to the coupler (3) and is configured to move the coupler (3) causing the coupler (3) to disengage from or engage with the follower (2).

Abstract: A method for probabilistic fatigue life prediction using nondestructive testing data considering uncertainties from nondestructive examination (NDE) data and fatigue model parameters. The method utilizes uncertainty quantification models for detection, sizing, fatigue model parameters and inputs. A probability of detection model is developed based on a log-linear model coupling an actual flaw size with a nondestructive examination (NDE) reported size. A distribution of the actual flaw size is derived for both NDE data without flaw indications and NDE data with flaw indications by using probabilistic modeling and Bayes theorem. A turbine rotor example with real world NDE inspection data is presented to demonstrate the overall methodology.

Abstract: The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: A new, improved grid spacer for a nuclear fuel assembly is provided, comprising several straps which intersect each other alternatively to form a plurality of grid cells and fuel rods reside in some of the grid cells; the grid spacer further comprises mixing elements set at the corner of the grid cells in which the fuel rods have resided; wherein the mixing element comprises a mixing vane stretching towards the direction of the fuel rod and a flow funnel set on the bended edge of the mixing vane continuously and extending towards adjacent grid cells; the mixing vane and the flow funnel set across two sides of two adjacent grid cells respectively, and the flow funnel introduces the coolant in the grid cell at its side to the mixing vane, then the mixing vane introduces the coolant to the grid cell at its own side.

Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: A multimedia redirection method, a multimedia server, and a computer system. The method includes: receiving a virtual-desktop login request of a user, where the virtual-desktop login request includes an identifier of the user; acquiring, according to the identifier of the user, metadata of a multimedia instance that is not shut down by the user before a last disconnection, where the metadata includes path information of a multimedia file corresponding to the multimedia instance; and sending the metadata to a client of the user so that the client acquires, according to the metadata, multimedia data corresponding to the metadata and plays the multimedia data. The adoption of technical solutions of the present invention can implement that multimedia that is not closed before a last disconnection may be automatically played when a user logs in again, thereby improving experience of multimedia application of the user.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: A clutch driving mechanism, comprising a motor, a worm, a torsion spring and a clutch rotating arm, wherein the motor is rotationally coupled with the worm, wherein the worm is operably coupled to at least a portion of the torsion spring, and the torsion spring is operably coupled to at least a portion of the clutch rotation arm.